{"name":"Novalar Pharmaceuticals, Inc.","slug":"novalar-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Phentolamine Mesylate (NV-101)","genericName":"Phentolamine Mesylate (NV-101)","slug":"phentolamine-mesylate-nv-101","indication":"Hypertension","status":"phase_3"}]}],"pipeline":[{"name":"Phentolamine Mesylate (NV-101)","genericName":"Phentolamine Mesylate (NV-101)","slug":"phentolamine-mesylate-nv-101","phase":"phase_3","mechanism":"Phentolamine mesylate is an alpha-adrenergic receptor antagonist that works by blocking the action of norepinephrine, a neurotransmitter that can cause blood vessels to constrict.","indications":["Hypertension","Pheochromocytoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2019-03-04","type":"pipeline","source":"openPR.com","summary":"General Anesthesia Drugs Market Share Forecast To Witness - openPR.com","headline":"General Anesthesia Drugs Market Share Forecast To Witness","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQa053T29kVDZ5OHhia1VyQXAyLUNyc18zUVNPSHBFekRBdURXN1NINFdqMEsydV92eWYzT3k5ZEZWYkxkLXdDdjYyeFBZUUc2ZUhhN2xleEZlRmFDb1Z1Z0J2LXlIWW9oejhIOFB2M1c4N0gxSnFsWmNvNUxEWHozUnZIVWNQZkFubG9XS1VMa2dHY0dMR0hnLWwyemEzLXMzclhmZTdKa1ZwNV9sMlF0UDNONVhwVE9EQ0E?oc=5","date":"2011-03-17","type":"deal","source":"DrBicuspid.com","summary":"Septodont acquires OraVerse from Novalar - DrBicuspid.com","headline":"Septodont acquires OraVerse from Novalar","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}